查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1529647

頭頸癌治療市場規模、佔有率、趨勢分析報告：依治療類型、給藥途徑、通路、地區、細分市場預測，2024-2030年

Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy), By Route Of Administration (Injectable, Oral), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

頭頸癌治療市場的成長與趨勢：

Grand View Research 的最新報告顯示，到 2030 年，全球頭頸癌治療市場規模預計將達到 44.3 億美元。

預計2024年至2030年該市場將以11.8%的複合年成長率成長。頭頸癌 (HNC) 診斷和治療的不斷進步預計將推動市場成長，因為它比手術更具成本效益且更有針對性。各類 HNC 盛行率的增加和老年人口的增加是市場的關鍵促進因素。

據癌症研究所稱，2021年美國約有54,000人被診斷出患有不同類型的HNC，約11,000人死亡。大量飲酒、長時間暴露在陽光下、致癌病毒感染（如EB病毒(EBV)）和菸草消費是導致全球各種頭頸癌發生率增加的一些主要因素。

此外，根據聯合國估計，到2020年，全球60歲以上人口將達到約7.27億。此外，老年人口預計將從2020年的9.3%增加到2050年的16%。老齡化會降低免疫力並增加對各種類型 HNC 的易感性，從而增加了對該疾病治療方法的需求。

此外，新型標靶藥物和多模式治療方法的研發活動的增加預計將提高頭頸癌患者的存活率。例如，默克/Debiopharm的Xevinapant目前正處於治療頭頸部鱗狀細胞癌的III期臨床試驗。它已被美國FDA指定為突破性療法。

支持性報銷政策預計也將推動市場成長。一些組織為患者及其看護者提供購買藥品的經濟援助。例如，2022 年 7 月，英國癌症協會將Capecitabine、卡鉑、Carboplatin、Cetuximab、Cisplatin、阿黴素、Fluorouracil和亞葉酸鈣列入其益處清單。此清單中包含的藥物有資格因其核准的適應症而獲得報銷。

頭頸癌治療市場報告亮點

  • 免疫療法引領市場，2023年佔全球收益佔有率的60.07%，預計在預測期內將以最快的複合年成長率成長。
  • 注射藥物將在 2023 年引領市場，預計在預測期內複合年成長率為 12.0%。注射劑在全身性治療中發揮重要作用，提供標靶藥物來對抗惡性癌細胞。
  • 零售和專業藥品在 2023 年以 57.67% 的市場佔有率引領市場，預計在預測期內將以最快的 CAR 成長。
  • 由於頭頸癌盛行率不斷上升、人們對惡性治療的認知不斷提高、可支配收入增加以及醫療改革取得進展，亞太地區頭頸癌治療市場預計將成為市場中成長最快的市場。

目錄

第1章調查方法與範圍

第2章執行概述

第3章頭頸癌治療市場變數、趨勢與範圍

  • 頭頸癌治療市場的系統展望
    • 母市場展望
    • 輔助市場
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 頭頸癌治療市場分析工具
    • 波特五力分析
    • 宏觀經濟分析
  • 管道分析
    • 臨床試驗三期管線藥物

第4章頭頸癌治療市場：依治療類型的業務分析

  • 頭頸癌治療市場：治療類型變異分析
  • 2023 年和 2030 年治療類型變化分析和市場佔有率
  • 化療
  • 免疫療法
  • 標靶治療

第5章頭頸癌治療市場：給藥途徑的業務分析

  • 頭頸癌治療市場：給藥途徑變化分析
  • 2023年及2030年給藥途徑變化分析及市場佔有率
  • 注射
  • 口服

第6章頭頸癌治療市場：通路的業務分析

  • 頭頸癌治療市場：通路波動分析
  • 2023年及2030年通路波動分析及市場佔有率
  • 零售/專業藥房
  • 醫院藥房
  • 網路藥房

第7章頭頸癌治療市場：區域估計與趨勢分析，依治療類型、給藥途徑、通路

  • 頭頸癌治療市場：區域展望
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 供應商情況
    • 2023年主要企業市場佔有率分析
    • Eli Lilly and Company
    • Sanofi
    • Merck &Co., Inc.
    • Cumberland Pharmaceuticals, Inc.
    • Bristol-Myers Squibb Company（BMS）
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries Ltd.
    • F. Hoffmann-La Roche Ltd
Product Code: GVR-2-68038-125-2

Head And Neck Cancer Therapeutics Market Growth & Trends:

The global head and neck cancer therapeutics market size is expected to reach USD 4.43 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 11.8% from 2024 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.

According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.

Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.

Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm's Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.

Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.

Head And Neck Cancer Therapeutics Market Report Highlights:

  • Immunotherapy led the market and accounted for 60.07% of the global revenue share in 2023 and is expected to grow at the fastest CAGR during the forecast period.
  • Injectable led the market in 2023 and is expected to grow at a CAGR of 12.0% over the forecast period. Injectable medications play an important role in systemic therapies, delivering targeted agents to combat malignancy cells.
  • Retail & specialty pharmacies led the market with a market share of 57.67% in 2023 and is expected to grow at the fastest CAR during the forecast period.
  • The head and neck cancer therapeutics market in Asia Pacific is anticipated to witness the fastest growth in the market owing to the increasing prevalence of head & neck cancer, growing awareness about malignancy treatment, rising disposable income, and increasing healthcare reforms.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Therapy Type
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Therapy Type and Route of Administration Segment Snapshot
  • 2.3 Distribution Channel Segment Snapshot
  • 2.4 Competitive Landscape Snapshot

Chapter 3 Head and Neck Cancer Therapeutics Market Variables, Trends, and Scope

  • 3.1 Head and Neck Cancer Therapeutics Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increase in Prevalence of Head and Neck Cancers
      • 3.2.1.2 Rising Geriatric Population
      • 3.2.1.3 Increasing R&D and Strong Presence of Pipeline Products
      • 3.2.1.4 Supportive Reimbursement Policies & Rising Awareness About Disease
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 Paucity of Data Related to Safety and Efficacy
      • 3.2.2.2 High Cost of Treatment
  • 3.3 Head and Neck Cancer Therapeutics Market Analysis Tools
    • 3.3.1 Porter's Five Forces Analysis
    • 3.3.2 Macroeconomic Analysis
  • 3.4 Pipeline Analysis
    • 3.4.1 Phase 3 Pipeline drugs under clinical trails

Chapter 4 Head and Neck Cancer Therapeutics Market: Therapy Type Business Analysis

  • 4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
  • 4.2 Therapy Type Movement Analysis & Market Share, 2023 & 2030
  • 4.3 Chemotherapy
    • 4.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.4 Immunotherapy
    • 4.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5 Targeted Therapy
    • 4.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5 Head and Neck Cancer Therapeutics Market: Route of Administration Business Analysis

  • 5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
  • 5.2 Route of Administration Movement Analysis & Market Share, 2023 & 2030
  • 5.3 Injectable
    • 5.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.4 Oral
    • 5.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6 Head and Neck Cancer Therapeutics Market: Distribution Channel Business Analysis

  • 6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
  • 6.2 Distribution Channel Movement Analysis & Market Share, 2023 & 2030
  • 6.3 Retail & Specialty Pharmacies
    • 6.3.1 Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.4 Hospital Pharmacies
    • 6.4.1 Market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5 Online Pharmacies
    • 6.5.1 Market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7 Head and Neck Cancer Therapeutics Market: Regional Estimates and Trend Analysis, by Therapy Type, by Route of Administration, by Distribution Channel

  • 7.1 Head and Neck Cancer Therapeutics Market: Regional Outlook
  • 7.2 North America
    • 7.2.1 North America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2 U.S.
      • 7.2.2.1 Key Country Dynamics
      • 7.2.2.2 U.S. Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.2.3 Target Disease: Cancer Incidence
      • 7.2.2.4 Market and Competitive Scenario
      • 7.2.2.5 Regulatory Framework
      • 7.2.2.6 Reimbursement Scenario
    • 7.2.3 Canada
      • 7.2.3.1 Key Country Dynamics
      • 7.2.3.2 Canada Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.2.3.3 Target Disease: Cancer Incidence
      • 7.2.3.4 Market and Competitive Scenario
      • 7.2.3.5 Regulatory Framework
      • 7.2.3.6 Reimbursement Scenario
  • 7.3 Europe
    • 7.3.1 Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2 UK
      • 7.3.2.1 Key Country Dynamics
      • 7.3.2.2 UK Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.2.3 Target Disease Prevalence
      • 7.3.2.4 Market and Competitive Scenario
      • 7.3.2.5 Regulatory Framework
      • 7.3.2.6 Reimbursement Scenario
    • 7.3.3 Germany
      • 7.3.3.1 Key Country Dynamics
      • 7.3.3.2 Germany Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.3.3 Target Disease Prevalence
      • 7.3.3.4 Market and Competitive Scenario
      • 7.3.3.5 Regulatory Framework
      • 7.3.3.6 Reimbursement Scenario
    • 7.3.4 France
      • 7.3.4.1 Key Country Dynamics
      • 7.3.4.2 France Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.4.3 Target Disease Prevalence
      • 7.3.4.4 Market and Competitive Scenario
      • 7.3.4.5 Regulatory Framework
      • 7.3.4.6 Reimbursement Scenario
    • 7.3.5 Spain
      • 7.3.5.1 Key Country Dynamics
      • 7.3.5.2 Spain Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.5.3 Target Disease Prevalence
      • 7.3.5.4 Market and Competitive Scenario
      • 7.3.5.5 Regulatory Framework
      • 7.3.5.6 Reimbursement Scenario
    • 7.3.6 Italy
      • 7.3.6.1 Key Country Dynamics
      • 7.3.6.2 Italy Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.6.3 Target Disease Prevalence
      • 7.3.6.4 Market and Competitive Scenario
      • 7.3.6.5 Regulatory Framework
      • 7.3.6.6 Reimbursement Scenario
    • 7.3.7 Denmark
      • 7.3.7.1 Key Country Dynamics
      • 7.3.7.2 Denmark Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.7.3 Target Disease Prevalence
      • 7.3.7.4 Market and Competitive Scenario
      • 7.3.7.5 Regulatory Framework
      • 7.3.7.6 Reimbursement Scenario
    • 7.3.8 Sweden
      • 7.3.8.1 Key Country Dynamics
      • 7.3.8.2 Sweden Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.8.3 Target Disease Prevalence
      • 7.3.8.4 Market and Competitive Scenario
      • 7.3.8.5 Regulatory Framework
      • 7.3.8.6 Reimbursement Scenario
    • 7.3.9 Norway
      • 7.3.9.1 Key Country Dynamics
      • 7.3.9.2 Norway Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.3.9.3 Target Disease Prevalence
      • 7.3.9.4 Market and Competitive Scenario
      • 7.3.9.5 Regulatory Framework
      • 7.3.9.6 Reimbursement Scenario
    • 7.3.10 Rest of Europe Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4 Asia Pacific
    • 7.4.1 Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2 Japan
      • 7.4.2.1 Key Country Dynamics
      • 7.4.2.2 Japan Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.2.3 Target Disease Prevalence
      • 7.4.2.4 Market and Competitive Scenario
      • 7.4.2.5 Regulatory Framework
      • 7.4.2.6 Reimbursement Scenario
    • 7.4.3 China
      • 7.4.3.1 Key Country Dynamics
      • 7.4.3.2 China Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.3.3 Target Disease Prevalence
      • 7.4.3.4 Market and Competitive Scenario
      • 7.4.3.5 Regulatory Framework
      • 7.4.3.6 Reimbursement Scenario
    • 7.4.4 India
      • 7.4.4.1 Key Country Dynamics
      • 7.4.4.2 India Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.4.3 Target Disease Prevalence
      • 7.4.4.4 Market and Competitive Scenario
      • 7.4.4.5 Regulatory Framework
      • 7.4.4.6 Reimbursement Scenario
    • 7.4.5 Australia
      • 7.4.5.1 Key Country Dynamics
      • 7.4.5.2 Australia Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.5.3 Target Disease Prevalence
      • 7.4.5.4 Market and Competitive Scenario
      • 7.4.5.5 Regulatory Framework
      • 7.4.5.6 Reimbursement Scenario
    • 7.4.6 Thailand
      • 7.4.6.1 Key Country Dynamics
      • 7.4.6.2 Thailand Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.6.3 Target Disease Prevalence
      • 7.4.6.4 Market and Competitive Scenario
      • 7.4.6.5 Regulatory Framework
      • 7.4.6.6 Reimbursement Scenario
    • 7.4.7 South Korea
      • 7.4.7.1 Key Country Dynamics
      • 7.4.7.2 South Korea Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.4.7.3 Target Disease Prevalence
      • 7.4.7.4 Market and Competitive Scenario
      • 7.4.7.5 Regulatory Framework
      • 7.4.7.6 Reimbursement Scenario
    • 7.4.8 Rest of Asia Pacific Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5 Latin America
    • 7.5.1 Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2 Brazil
      • 7.5.2.1 Key Country Dynamics
      • 7.5.2.2 Brazil Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.2.3 Target Disease Prevalence
      • 7.5.2.4 Competitive Scenario
      • 7.5.2.5 Regulatory Framework
      • 7.5.2.6 Reimbursement Scenario
    • 7.5.3 Mexico
      • 7.5.3.1 Key Country Dynamics
      • 7.5.3.2 Mexico Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.3.3 Target Disease: Cancer Incidence
      • 7.5.3.4 Market and Competitive Scenario
      • 7.5.3.5 Regulatory Framework
      • 7.5.3.6 Reimbursement Scenario
    • 7.5.4 Argentina
      • 7.5.4.1 Key Country Dynamics
      • 7.5.4.2 Argentina Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.5.4.3 Target Disease Prevalence
      • 7.5.4.4 Competitive Scenario
      • 7.5.4.5 Regulatory Framework
      • 7.5.4.6 Reimbursement Scenario
    • 7.5.5 Rest of Latin America Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6 Middle East and Africa
    • 7.6.1 MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2 South Africa
      • 7.6.2.1 Key Country Dynamics
      • 7.6.2.2 South Africa Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.2.3 Target Disease Prevalence
      • 7.6.2.4 Competitive Scenario
      • 7.6.2.5 Regulatory Framework
      • 7.6.2.6 Reimbursement Scenario
    • 7.6.3 Saudi Arabia
      • 7.6.3.1 Key Country Dynamics
      • 7.6.3.2 Saudi Arabia Head and Neck Cancer Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
      • 7.6.3.3 Target Disease Prevalence
      • 7.6.3.4 Competitive Scenario
      • 7.6.3.5 Regulatory Framework
      • 7.6.3.6 Reimbursement Scenario
    • 7.6.4 UAE
      • 7.6.4.1 Key Country Dynamics
      • 7.6.4.2 UAE Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.4.3 Target Disease Prevalence
      • 7.6.4.4 Competitive Scenario
      • 7.6.4.5 Regulatory Framework
      • 7.6.4.6 Reimbursement Scenario
    • 7.6.5 Kuwait
      • 7.6.5.1 Key Country Dynamics
      • 7.6.5.2 Kuwait Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 7.6.5.3 Target Disease Prevalence
      • 7.6.5.4 Competitive Scenario
      • 7.6.5.5 Regulatory Framework
      • 7.6.5.6 Reimbursement Scenario
    • 7.6.6 Rest of MEA Head and Neck Cancer Therapeutics Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Competitive Landscape

  • 8.1 Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2 Company Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Eli Lilly and Company
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Sanofi
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.6. Merck & Co., Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.7. Cumberland Pharmaceuticals, Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.8. Bristol-Myers Squibb Company (BMS)
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.9. AstraZeneca
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.10. Takeda Pharmaceutical Company Limited
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.11. Teva Pharmaceutical Industries Ltd.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.12. F. Hoffmann-La Roche Ltd
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Head and Neck Cancer Therapeutics Market, By Region, 2018 - 2030 (USD Million)
  • Table 4 Global Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 5 Global Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 6 Global Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 8 North America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 9 North America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 10 U.S. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 11 U.S. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 13 Canada Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 14 Canada Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 15 Canada Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 16 Europe Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 17 Europe Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 18 Europe Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 20 Germany Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 21 Germany Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 22 UK Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 23 UK Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 24 UK Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 25 France Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 26 France Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 27 France Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 29 Italy Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 30 Italy Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 32 Spain Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 33 Spain Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 37 Japan Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 38 Japan Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 39 Japan Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 40 China Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 41 China Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 42 China Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 India Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 44 India Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 45 India Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 South Korea Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 47 South Korea Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 48 South Korea Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 Australia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 50 Australia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 51 Australia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Latin America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 53 Latin America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 54 Latin America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 55 Brazil Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 56 Brazil Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 57 Brazil Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 58 Mexico Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 59 Mexico Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 60 Mexico Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 61 Argentina Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 62 Argentina Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 63 Argentina Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 64 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 65 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 66 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 67 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 68 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 69 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 70 South Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 71 South Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 72 South Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 UAE Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
  • Table 74 UAE Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
  • Table 75 UAE Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Head And neck cancer therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Therapy type and route of administration segment snapshot
  • Fig. 11 Distribution channel segment snapshot
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Head and neck cancer therapeutics market: Therapy type outlook & key takeaways
  • Fig. 17 Head and neck cancer therapeutics market: Therapy type movement analysis
  • Fig. 18 Global chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Global immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 20 Global targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 21 Head and neck cancer therapeutics market: Route of administration outlook & key takeaways
  • Fig. 22 Head and neck cancer therapeutics market: Route of administration movement analysis
  • Fig. 23 Global injectable market, 2018 - 2030 (USD Million)
  • Fig. 24 Global oral market, 2018 - 2030 (USD Million)
  • Fig. 25 Head and neck cancer therapeutics market: Distribution channel outlook & key takeaways
  • Fig. 26 Head and neck cancer therapeutics market: Distribution channel movement analysis
  • Fig. 27 Global retail & specialty pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 28 Global hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 29 Global online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 30 Head and neck cancer therapeutics market revenue, by region, 2023 & 2030 (USD Million)
  • Fig. 31 Regional marketplace: Key takeaways
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Key country dynamics
  • Fig. 35 U.S. head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. oropharynx cancer: Estimated number of new cases, 2020 - 2040
  • Fig. 37 Key country dynamics
  • Fig. 38 Canada head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Canada: oropharynx cancer: Estimated number of new cases, 2020 - 2040
  • Fig. 40 Key country dynamics
  • Fig. 41 Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Key country dynamics
  • Fig. 43 UK head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 45 Key country dynamics
  • Fig. 46 Germany head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Oropharynx cancer incidence, 2020 - 2030
  • Fig. 48 Germany insurance coverage
  • Fig. 49 Key country dynamics
  • Fig. 50 France head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 52 Key country dynamics
  • Fig. 53 Spain head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 55 Key country dynamics
  • Fig. 56 Italy head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Larynx cancer incidence, 2020 - 2030
  • Fig. 58 Key country dynamics
  • Fig. 59 Denmark head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Oropharynx Cancer Incidence, 2020 - 2030
  • Fig. 61 Key country dynamics
  • Fig. 62 Sweden head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 64 Key country dynamics
  • Fig. 65 Norway head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 67 Rest of Europe head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Japan head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 71 Japan pharmaceutical registration
  • Fig. 72 Key country dynamics
  • Fig. 73 China head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 74 Nasopharynx cancer incidence, 2020 - 2030
  • Fig. 75 Regulatory details: China
  • Fig. 76 Exclusivity formula
  • Fig. 77 Key country dynamics
  • Fig. 78 India head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 79 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 80 Registration details: India
  • Fig. 81 Key country dynamics
  • Fig. 82 Australia head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 83 Lip, Oral Cavity Cancer incidence, 2020 to 2030
  • Fig. 84 Drug pricing: Australia
  • Fig. 85 Contribution of PBS by disease
  • Fig. 86 Key country dynamics
  • Fig. 87 Thailand head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 88 Nasopharynx Cancer incidence, 2020 to 2030
  • Fig. 89 Key country dynamics
  • Fig. 90 South Korea head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 91 Lip, Oral Cavity Cancer incidence 2020 to 2030
  • Fig. 92 Reimbursement scenario: South Korea
  • Fig. 93 Rest of Asia Pacific head and neck cancer therapeutics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 94 Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Key country dynamics
  • Fig. 96 Brazil head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 Larynx Cancer Incidence, 2020 to 2030
  • Fig. 98 Regulatory framework
  • Fig. 99 Reimbursement scenario
  • Fig. 100 Key country dynamics
  • Fig. 101 Mexico head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Mexico: oropharynx cancer: Estimated number of new cases, 2020 - 2040
  • Fig. 103 Argentina head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 104 Larynx cancer incidence, 2020 to 2030
  • Fig. 105 Argentina pharmaceuticals registration details
  • Fig. 106 Argentina pharmaceuticals reimbursement details
  • Fig. 107 Rest of Latin America head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 Key country dynamics
  • Fig. 110 South Africa head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 111 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 112 Regulatory framework: South Africa
  • Fig. 113 Regulatory framework: South Africa drug registration fees
  • Fig. 114 Key country dynamics
  • Fig. 115 Saudi Arabia head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Nasopharynx cancer incidence, 2020 to 2030
  • Fig. 117 Key country dynamics
  • Fig. 118 UAE head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 120 Key country dynamics
  • Fig. 121 Kuwait head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Lip, oral cavity cancer incidence, 2020 - 2030
  • Fig. 123 Regulatory framework: Kuwait
  • Fig. 124 Rest of MEA head and neck cancer therapeutics market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 125 Key company categorization
  • Fig. 126 Company market share analysis, 2023
  • Fig. 127 Strategic framework